Author's response to reviews

Title: Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein

Authors:

Emiliano Pavoni (pavoni@kenton.it)
Michela Flego (flego@iss.it)
Maria Luisa Dupuis (mldupuis@iss.it)
Stefano Barca (sbarca@iss.it)
Fiorella Petronzelli (fiorella.petronzelli@sigma-tau.it)
Anna Maria Anastasi (annamaria.anastasi@sigma-tau.it)
Valeria D'Alessio (valeria.dalessio@sigma-tau.it)
Angela Pelliccia (angela.pelliccia@sigma-tau.it)
Paola Vaccaro (vaccaro@kenton.it)
Giorgia Monteriu (monteriu@kenton.it)
Alessandro Ascione (fiano1974@yahoo.it)
Rita De Santis (rita.desantis@sigma-tau.it)
Franco Felici (felici@kenton.it)
Maurizio Cianfriglia (cianfri@iss.it)
Olga Minenkova (minenkova@kenton.it)

Version: 3 Date: 30 January 2006

Author's response to reviews: see over
Dear Editors,

Please find the revised version of the manuscript “Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein” by Pavoni et al., submitted online.

I report below how we have addressed the reviewer’s comments and which modifications have been introduced into the Revised Version.

Reviewer: Rhona Stein
Minor Revisions:
1. In revised version is now written:” strongly binds tumors”, p.13, line 18.
2. In revised version is now written:” dashed line represents background”, Figure legends, Figure 7, p.17, line 37.

I confirm that the authors of the manuscript have no competing interests to declare. The institutions (Kenton, s.r.l.; Sigma-Tau, s.p.a.) contributed for experimental development of the described research and paid salary to researchers, and the article-processing charge will not gain or lose financially from the publication of the manuscript. We are not applying currently for any patent relating to the content of the manuscript. We have no any other financial or non-financial competing interests.

We checked the manuscript format as follows:
1. The heading ‘Research article’ is removed from the title page.
2. The Keyword section is removed from the manuscript.
3. The title of the article now is printed ‘in bold’, using Arial, with letter size 16.
4. All section headings are printed, using Arial with letters size 16 (section headings) or 11 (sub-section headings).
5. All sections and sub-sections of the manuscript are divided now by a one-line space.
6. Final points were removed from the title of the article, and from each headings in the Figures, and the Tables sections.
7. The legend text in each Figure is now printed on a new line.

All authors of the article agree to submit the manuscript in present form to BMC Cancer.

Sincerely, Minenkova O., Ph.D.
Kenton Labs,
c/o Sigma-Tau, via Pontina, km 30.400,
Pomezia (RM), 00040, Italy
FAX: 39-06-91629012
e-mail: minenkova@kenton.it